Arena Pharmaceutical (ARNA) 1.86 $ARNA How These

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 12:22 PM

Arena Pharmaceutical (ARNA) 1.86 $ARNA

How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 86.42 (+1.20), XON: 24.80 (+0.15), ARNA: 1.86 (+0.01), REGN: 357.24 (+5.32)

Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.86 (+0.01)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.49 (+0.03), RTRX: 18.71 (+0.23), VVUS: 1.10 (unch), ARNA: 1.86 (+0.01)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.86 (+0.01)

Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 34.19 (+0.29), CBM: 49.31 (+1.14), ANIP: 56.20 (+3.41), ARNA: 1.86 (+0.01)

Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.86 (+0.01)

Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.86 (+0.01)

Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.86 (+0.01)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.31 (-0.02), INO: 9.71 (-0.49), VVUS: 1.10 (unch), TEVA: 51.43 (+0.24), ARNA: 1.86 (+0.01), PBYI: 33.29 (+1.76)

Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.27 (+0.02), JAZZ: 143.65 (+0.71), VVUS: 1.10 (unch), ARNA: 1.86 (+0.01)

Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9
PR Newswire - Mon May 02, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter 2016 financial results and provide a corporate update. Arena will issue a press release with its financial results after the NASDAQ Global Select Market closes that day.
ARNA: 1.86 (+0.01)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 10.40 (+0.10), ALIM: 1.53 (+0.02), ARES: 14.05 (+0.35), AXTA: 28.63 (+0.67), ARNA: 1.86 (+0.01)

Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 30.59 (-0.74), AMAG: 24.44 (-0.02), ANIK: 51.10 (+0.83), ARNA: 1.86 (+0.01)

Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial of APD371
PR Newswire - Tue Apr 12, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain.
ARNA: 1.86 (+0.01)

New Strong Sell Stocks for April 7th
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:51AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXTI: 3.40 (+0.07), AMD: 5.22 (+0.20), ARES: 14.05 (+0.35), AWI: 40.42 (+0.28), ARNA: 1.86 (+0.01)

Stocks to Watch for Tuesday 3/22/2016, If You Choose
ACCESSWIRE - Tue Mar 22, 10:31AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 22, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FBEC, ARNA, AXU, and LEU have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
ARNA: 1.86 (+0.01)

Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead
Arpita Dutt - Zacks Investment Research - Tue Mar 15, 9:15AM CDT
It could be challenging to pick winners in this "high risk and high returns" industry which is constantly growing and changing.
MDVN: 59.12 (+0.23), GILD: 83.41 (+0.96), AMGN: 152.10 (+2.29), SNY: 40.90 (+0.61), ARNA: 1.86 (+0.01), REGN: 357.24 (+5.32)

Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 83.41 (+0.96), AMGN: 152.10 (+2.29), ABBV: 61.02 (+0.63), MNTA: 10.81 (+0.18), ARNA: 1.86 (+0.01), REGN: 357.24 (+5.32), CELG: 100.32 (+1.09)

New Strong Sell Stocks for March 8th
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 8:56AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
AMBA: 50.94 (-0.46), AXTI: 3.40 (+0.07), ARES: 14.05 (+0.35), ASC: 7.60 (-0.02), ARNA: 1.86 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....